Gilead warning cites animated operator

An animated operator has helped land Gilead an FDA warning letter. But the company was cited for a variety of violations that go beyond operator antics.

In the late September letter, which stems from an inspection at the beginning of the year of the company's San Dimas, CA, facility, the regulator cites the drugmaker for an instance of an excited aseptic fill operator who neglected procedures intended to prevent microbiological contamination of drug products. The procedures call for personnel "to make slow, deliberate movements during manufacturing operations," the letter states. Inspectors noted, however, an operator "making excessive body and hand movements and engaging in animated conversations."

Among the other violations is failure to maintain defined operations areas to prevent contamination and product mix-ups; a sub-par airflow assessment technique; inadequate written procedures for controls that assure product identity, strength, quality and purity; and lack of investigation into a product failure. The latter case involves tablet-process re-validation lots that repeatedly failed visual inspection. Rather than investigating the cause, operators culled defective tablets and packaged the remainder, according to the letter.

- here's Warning Letter W/L 44-10

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.